Early-phase studies have evaluated B7-H3 ADCs in extensive-stage small cell lung cancer patients [122,123], and PD-L1 ADCs are being evaluated in phase 1 studies of solid tumors [124]. This evidence concerns the gene CD274 and small cell lung carcinoma.